Summary
Bristol Myers Squibb (BMY) reported its third-quarter 2020 results, showcasing continued integration of the Celgene acquisition and its impact on the company's financial performance. Revenue growth was driven by strong performance in key therapeutic areas, particularly oncology and immunology. The company's strategic focus on its in-line and new product portfolio, alongside pipeline advancements, appears to be yielding positive results, as evidenced by the reported sales figures and the progress in key clinical trials. Investors should monitor the ongoing integration efforts and the company's ability to sustain revenue growth from its newly acquired assets while managing operational expenses and debt.
Financial Highlights
57 data pointsBeta
Financial Statements
Beta
| Revenue | $10.54B |
| Cost of Revenue | $2.50B |
| Gross Profit | $8.04B |
| R&D Expenses | $2.50B |
| SG&A Expenses | $1.71B |
| Operating Expenses | $8.28B |
| Interest Expense | $346.00M |
| Net Income | $1.87B |
| EPS (Basic) | $0.83 |
| EPS (Diluted) | $0.82 |
| Shares Outstanding (Basic) | 2.26B |
| Shares Outstanding (Diluted) | 2.29B |
Key Highlights
- 1Strong revenue performance driven by key products like Revlimid, Pomalyst/Imnovid, and Eliquis.
- 2Continued progress in integrating the Celgene acquisition, contributing significantly to overall sales.
- 3Net sales increased by a notable percentage compared to the prior year's third quarter, reflecting growth in both in-line and acquired products.
- 4Diluted earnings per share (EPS) showed improvement, indicating enhanced profitability.
- 5The company maintained a solid cash flow from operations, supporting ongoing investments and debt repayment.
- 6Progress reported in advancing the company's pipeline, with several key drugs in late-stage development.